person · Reporting owner

Leiderman Elisabeth

Disclosed activity across 3 companies

Tapewire entity: 33771
SEC CIK: 0001842133

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Autolus Therapeutics plcAUTL · Entity 1933	Director	June 29, 2026	July 01, 2026
Decibel Therapeutics, Inc.DBTX · Entity 109458	Chief Financial Officer	February 25, 2022	February 28, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Autolus Therapeutics plc

Report date June 29, 2026 · Filed July 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	31,667	Reported balance After 2026-06-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-29 · Grant · Acquired 31,667 · Balance 31,667 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. F2: The RSUs vest in one installment on June 29, 2027.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2036-06-29	Direct	47,500	Reported balance After 2026-06-29 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-29 · Grant · Acquired 47,500 · Balance 47,500 F3: Share options vest in twelve equal monthly installments commencing on July 29, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share.

F2: The RSUs vest in one installment on June 29, 2027.

F3: Share options vest in twelve equal monthly installments commencing on July 29, 2026.

Decibel Therapeutics, Inc.

Report date February 25, 2022 · Filed February 28, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.50 · Expires 2032-02-24	Direct	52,500	Reported balance After 2022-02-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-02-25 · Grant · Acquired 52,500 · Balance 52,500 F1: The option was granted on February 25, 2022. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 25, 2023 and with respect to the remainder in 36 equal monthly installments thereafter through February 25, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted on February 25, 2022. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 25, 2023 and with respect to the remainder in 36 equal monthly installments thereafter through February 25, 2026.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

bluebird bio, Inc.

Report date May 30, 2025 · Filed June 03, 2025

Section 16 reporting ended · disclosed 2025-06-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2025-06-02 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2025-05-30 · Other · Disposed 1,112 · Balance 1,245 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Row 2 · 2025-06-02 · Disposition to issuer · Disposed 1,245 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive F4: (Continued from footnote 3) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price").

F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive

F4: (Continued from footnote 3) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 29, 2026 Filed Jul 1, 2026 20:15 UTC	Autolus Therapeutics plc AUTL · Entity 1933	GrantShare Option (Right to Buy) · Derivative	47,500	$0.00 Strike: $1.61	$0.00	Disclosure SEC source: 0001730463-26-000101 · form4.xml · derivative · entry 2 Leiderman Elisabeth · CIK 0001842133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: American Depositary Shares · 47,500 shares Expires 2036-06-29 F3 · derivative.exercise_date: Share options vest in twelve equal monthly installments commencing on July 29, 2026. Read SEC document
June 29, 2026 Filed Jul 1, 2026 20:15 UTC	Autolus Therapeutics plc AUTL · Entity 1933	GrantRestricted Share Units · Derivative	31,667	$0.00	$0.00	Disclosure SEC source: 0001730463-26-000101 · form4.xml · derivative · entry 1 Leiderman Elisabeth · CIK 0001842133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,667 Underlying: American Depositary Shares · 31,667 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. F2 · derivative.exercise_date: The RSUs vest in one installment on June 29, 2027. F2 · derivative.expiration_date: The RSUs vest in one installment on June 29, 2027. Read SEC document
June 02, 2025 Filed Jun 3, 2025 17:29 UTC	bluebird bio, Inc. BLUE · Entity 78923	Disposition to issuerCommon Stock	1,245	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-081135 · ownership.xml · nonDerivative · entry 2 Leiderman Elisabeth · CIK 0001842133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive F4 · price: (Continued from footnote 3) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time. Read SEC document
May 30, 2025 Filed Jun 3, 2025 17:29 UTC	bluebird bio, Inc. BLUE · Entity 78923	OtherCommon Stock	1,112	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-081135 · ownership.xml · nonDerivative · entry 1 Leiderman Elisabeth · CIK 0001842133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,245 F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2 · price: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Read SEC document
November 06, 2024 Filed Nov 8, 2024 16:08 UTC	bluebird bio, Inc. BLUE · Entity 78923	GrantStock Option (right to buy) · Derivative	49,850	$0.00 Strike: $0.44	$0.00	Disclosure SEC source: 0001562180-24-007604 · primarydocument.xml · derivative · entry 2 Leiderman Elisabeth · CIK 0001842133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,850 Underlying: Common Stock · 49,850 shares Expires 2034-11-06 F2 · derivative.exercise_date: This option vests 100% on the earlier of November 6, 2025 or the date of the next annual meeting of stockholders. Read SEC document
November 06, 2024 Filed Nov 8, 2024 16:08 UTC	bluebird bio, Inc. BLUE · Entity 78923	GrantCommon Stock	24,900	$0.00	$0.00	Disclosure SEC source: 0001562180-24-007604 · primarydocument.xml · nonDerivative · entry 1 Leiderman Elisabeth · CIK 0001842133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,156 F1 · security: These restricted stock units for common stock vest 100% on the earlier of November 6, 2025 or the date of the next annual meeting of stockholders. Read SEC document
June 16, 2023 Filed Jun 20, 2023 16:30 UTC	bluebird bio, Inc. BLUE · Entity 78923	GrantStock Option (right to buy) · Derivative	21,600	$0.00 Strike: $3.81	$0.00	Disclosure SEC source: 0001562180-23-005351 · primarydocument.xml · derivative · entry 2 Leiderman Elisabeth · CIK 0001842133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,600 Underlying: Common Stock · 21,600 shares Expires 2033-06-16 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 16, 2024 or the date of the next annual meeting of stockholders. Read SEC document
June 16, 2023 Filed Jun 20, 2023 16:30 UTC	bluebird bio, Inc. BLUE · Entity 78923	GrantCommon Stock	10,790	$0.00	$0.00	Disclosure SEC source: 0001562180-23-005351 · primarydocument.xml · nonDerivative · entry 1 Leiderman Elisabeth · CIK 0001842133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,256 F1 · security: These restricted stock units for common stock vest 100% on the earlier of June 16, 2024 or the date of the next annual meeting of stockholders. Read SEC document
October 17, 2022 Filed Mar 9, 2023 16:06 UTC	bluebird bio, Inc. BLUE · Entity 78923	SaleCommon Stock	1,004	$6.46	$6,490.16	Disclosure SEC source: 0001562180-23-002662 · primarydocument.xml · nonDerivative · entry 1 Leiderman Elisabeth · CIK 0001842133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,466 F1 · kind: Shares were mistakenly sold to cover tax withholding obligations incurred in connection with the vesting of restricted stock units. F2 · price: The range in prices for the transaction reported on this line was $6.4614 to $6.4671. The average weighted price was $6.4643. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
June 22, 2022 Filed Jun 23, 2022 18:08 UTC	bluebird bio, Inc. BLUE · Entity 78923	GrantStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $4.46	$0.00	Disclosure SEC source: 0001562180-22-005336 · primarydocument.xml · derivative · entry 2 Leiderman Elisabeth · CIK 0001842133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-06-22 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 22, 2023 or the date of the next annual meeting of stockholders. Read SEC document
June 22, 2022 Filed Jun 23, 2022 18:08 UTC	bluebird bio, Inc. BLUE · Entity 78923	GrantCommon Stock	3,109	$0.00	$0.00	Disclosure SEC source: 0001562180-22-005336 · primarydocument.xml · nonDerivative · entry 1 Leiderman Elisabeth · CIK 0001842133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,470 F1 · security: These restricted stock units for common stock vest 100% on the earlier of June 22, 2023 or the date of the next annual meeting of stockholders. Read SEC document
February 25, 2022 Filed Feb 28, 2022 16:37 UTC	Decibel Therapeutics, Inc. DBTX · Entity 109458	GrantStock Options (right to buy) · Derivative	52,500	$0.00 Strike: $3.50	$0.00	Disclosure SEC source: 0000899243-22-008087 · doc4.xml · derivative · entry 1 Leiderman Elisabeth · CIK 0001842133 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2032-02-24 F1 · derivative.exercise_date: The option was granted on February 25, 2022. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 25, 2023 and with respect to the remainder in 36 equal monthly installments thereafter through February 25, 2026. Read SEC document
November 11, 2021 Filed Nov 16, 2021 06:26 UTC	bluebird bio, Inc. BLUE · Entity 78923	Disposition to issuerStock Option (right to buy) · Derivative	15,057	$0.00 Strike: $10.41	$0.00	Disclosure SEC source: 0001628280-21-023460 · wf-form4_163706189742341.xml · derivative · entry 2 Leiderman Elisabeth · CIK 0001842133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,057 Underlying: Common Stock · 15,057 shares Expires 2031-10-15 F4 · derivative.exercise_price: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on October 15, 2021 and shall vest over three years in annual installments commencing on October 15, 2021. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F4 · shares: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on October 15, 2021 and shall vest over three years in annual installments commencing on October 15, 2021. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F4 · derivative.exercise_date: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on October 15, 2021 and shall vest over three years in annual installments commencing on October 15, 2021. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. Read SEC document
November 11, 2021 Filed Nov 16, 2021 06:26 UTC	bluebird bio, Inc. BLUE · Entity 78923	OtherCommon Stock	9,361	$0.00	$0.00	Disclosure SEC source: 0001628280-21-023460 · wf-form4_163706189742341.xml · nonDerivative · entry 1 Leiderman Elisabeth · CIK 0001842133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,361 F1 · security: Represents restricted stock units awarded to the reporting person prior to the separation (the "Separation") of 2seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the the Employee Matters Agreement by and between 2seventy and bluebird (the "EMA") to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on October 15, 2021 and vests ratably over three years in annual installments commencing on October 15, 2021. F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP. Read SEC document
October 15, 2021 Filed Oct 19, 2021 20:00 UTC	bluebird bio, Inc. BLUE · Entity 78923	GrantStock Option (right to buy) · Derivative	7,500	$0.00 Strike: $20.90	$0.00	Disclosure SEC source: 0001562180-21-006578 · primarydocument.xml · derivative · entry 2 Leiderman Elisabeth · CIK 0001842133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-10-15 F2 · derivative.exercise_date: This option vests ratably over three years in annual installments commencing on October 15, 2021. Read SEC document
October 15, 2021 Filed Oct 19, 2021 20:00 UTC	bluebird bio, Inc. BLUE · Entity 78923	GrantCommon Stock	4,663	$0.00	$0.00	Disclosure SEC source: 0001562180-21-006578 · primarydocument.xml · nonDerivative · entry 1 Leiderman Elisabeth · CIK 0001842133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,663 F1 · security: These restricted stock units for common stock vest ratably over three years in annual installments commencing on October 15, 2021. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.